NGHIÊN CỨU ĐẶC ĐIỂM BỆNH NHÂN THỰC HIỆN PHƯƠNG PHÁP PHÂN TÍCH DI TRUYỀN TRƯỚC CHUYỂN PHÔI KHÔNG XÂM LẤNĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG VÀ TÍNH AN TOÀN CỦA PHƯƠNG PHÁP TẮC MẠCH HÓA CHẤT SIÊU CHỌN LỌC SỬ DỤNG HẠT VI CẦU DC BEAD M1 TRONG ĐIỀU TRỊ UNG THƯ BIỂ

Abstract

Objective: To evaluate the clinical and paraclinical characteristics and safety of superselective transarterial chemoembolization (DEB-TACE) using DC Bead M1 microspheres in patients with early-stage hepatocellular carcinoma (HCC). Methods: A prospective study was conducted on 35 patients with BCLC-A stage HCC, Child-Pugh A, who underwent superselective DEB-TACE with DC Bead M1 microspheres (70–150 µm) loaded with doxorubicin at the 108 Military Central Hospital from June 2024 to May 2025. Clinical, paraclinical parameters, and adverse events within 48 hours post-intervention were evaluated. Results: The mean age of the patients was 63.4±11.7 years, with a male-to-female ratio of 4.8:1. The majority had a history of Hepatitis B virus (60.0%), were newly diagnosed (88.6%), and had an ECOG -0 (85.7%). Common symptoms included right hypochondrial pain (31.4%) and fatigue (28.6%). Median AFP was 11.18 ng/mL (IQR: 4.38–122.72), and median PIVKA-II was 170 mAU/mL (IQR: 41.84–617.01). Most tumors were solitary (97.2%) with a mean tumor size of 3.55±0.86 cm. Adverse events post-intervention included liver pain (51.4%), nausea/vomiting (25.7%), and fatigue (17.1%), which were predominantly mild and self-limiting. Conclusion: Super-selective TACE using DC Bead M1 microspheres demonstrates high safety and is appropriate as bridging therapy in multimodal treatment strategies for early-stage HCC.